PE20221461A1 - Heteroarilaminosulfonamidas de 5 miembros para tratar afecciones mediadas por una actividad deficiente de cftr - Google Patents

Heteroarilaminosulfonamidas de 5 miembros para tratar afecciones mediadas por una actividad deficiente de cftr

Info

Publication number
PE20221461A1
PE20221461A1 PE2022000772A PE2022000772A PE20221461A1 PE 20221461 A1 PE20221461 A1 PE 20221461A1 PE 2022000772 A PE2022000772 A PE 2022000772A PE 2022000772 A PE2022000772 A PE 2022000772A PE 20221461 A1 PE20221461 A1 PE 20221461A1
Authority
PE
Peru
Prior art keywords
membered
substituted
conditions mediated
cftr activity
heteroarylaminosulfonamides
Prior art date
Application number
PE2022000772A
Other languages
English (en)
Inventor
Junkai Liao
Mark Munson
Zhongli Gao
Gregory Hurlbut
Sylvie Baltzer
Bertrand Vivet
Brian Freed
Hans Peter Nestler
Helen Yeoman
Ingrid Mechin
Martin Smrcina
Nina Ma
Sylvain Lebreton
Ryan Hartung
William Wire
Sukanthini Thurairatnam
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of PE20221461A1 publication Critical patent/PE20221461A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/50—Nitrogen atoms bound to hetero atoms
    • C07D277/52—Nitrogen atoms bound to hetero atoms to sulfur atoms, e.g. sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/22—Amides of acids of phosphorus
    • C07F9/222—Amides of phosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6536—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and sulfur atoms with or without oxygen atoms, as the only ring hetero atoms
    • C07F9/6539—Five-membered rings

Abstract

La invencion se refiere a compuestos heteroarilaminosulfonamida de 5 miembros de formula (I), o una sal farmaceuticamente aceptable de esta; en donde R1 es CH o alquilo C1-6; X es alquilo C1-6, arilo de 5-6 miembros, heterocicloalquilo de 4-10 miembros o heteroarilo de 5-6 miembros, cada uno sustituido con 0-3 R2; Cy1 es cicloalquilo C3-9, arilo de 5-6 miembros, heterocicloalquilo de 4-10 miembros o heteroarilo de 5-6 miembros, cada uno sustituido con 0-3 R3 ; Cy2 es cicloalquilo C3-9, arilo de 5-6 miembros, heterocicloalquilo de 4-10 miembros o heteroarilo de 5-6 miembros, cada uno sustituido con 1-3 R4. Un compuesto seleccionado es 6-amino-N-(5-(3-(3,3-dimetilbutoxi)-5-fluorofenil)-4-(4-fluoro-2-((1,1,1-trifluoropropan-2-il)oxi)fenil)tiazol-2-il)piridin-2-sulfonamida. Dichos compuestos actuan como correctores de CFTR (regulador de conductancia transmembrana de fibrosis quistica). Tambien proporcionan una composicion farmaceutica que los comprende; siendo utiles para tratar enfermedades y afecciones mediadas por la actividad de CFTR deficiente, en particular la fibrosis quistica.
PE2022000772A 2019-11-12 2020-11-12 Heteroarilaminosulfonamidas de 5 miembros para tratar afecciones mediadas por una actividad deficiente de cftr PE20221461A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962934293P 2019-11-12 2019-11-12
PCT/US2020/060180 WO2021097057A1 (en) 2019-11-12 2020-11-12 5-membered heteroarylaminosulfonamides for treating conditions mediated by deficient cftr activity

Publications (1)

Publication Number Publication Date
PE20221461A1 true PE20221461A1 (es) 2022-09-21

Family

ID=73740547

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2022000772A PE20221461A1 (es) 2019-11-12 2020-11-12 Heteroarilaminosulfonamidas de 5 miembros para tratar afecciones mediadas por una actividad deficiente de cftr

Country Status (16)

Country Link
US (1) US20240002374A1 (es)
EP (1) EP4058439A1 (es)
JP (1) JP2023500408A (es)
KR (1) KR20220115829A (es)
CN (1) CN115003659A (es)
AU (1) AU2020384279A1 (es)
BR (1) BR112022009185A2 (es)
CA (1) CA3158057A1 (es)
CL (1) CL2022001245A1 (es)
CO (1) CO2022007953A2 (es)
EC (1) ECSP22046050A (es)
IL (1) IL292966A (es)
JO (1) JOP20220105A1 (es)
MX (1) MX2022005809A (es)
PE (1) PE20221461A1 (es)
WO (1) WO2021097057A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3752510T (pt) 2018-02-15 2023-03-15 Vertex Pharma Macrociclos como moduladores do regulador de condutância de transmembrana da fibrose cística, suas composições farmacêuticas, seu uso no tratamento da fibrose cística e processos para produzi-los
TW202115092A (zh) 2019-08-14 2021-04-16 美商維泰克斯製藥公司 囊腫纖維化跨膜傳導調節蛋白之調節劑
EP4013760A1 (en) 2019-08-14 2022-06-22 Vertex Pharmaceuticals Incorporated Crystalline forms of cftr modulators
TW202120517A (zh) 2019-08-14 2021-06-01 美商維泰克斯製藥公司 製備cftr調節劑之方法
EP4225737A1 (en) * 2020-10-07 2023-08-16 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
CN113480416B (zh) * 2021-07-12 2023-03-21 重庆大学 一种芳基酮的制备方法
CN114835655A (zh) * 2022-04-14 2022-08-02 河南师范大学 一种合成光学活性三氟甲基丙烯酸酯类化合物的方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0592664B1 (en) * 1991-03-07 2000-07-05 Hisamitsu Pharmaceutical Co., Inc. Derivatives of diphenylthiazole with antiinflammatory activity
WO1996016650A1 (fr) * 1994-11-29 1996-06-06 Hisamitsu Pharmaceutical Co., Inc. Antibacterien et bactericide comprenant un derive de 2-aminothiazole et sels de ce derive
EP1441732A2 (en) * 2001-11-08 2004-08-04 Fujisawa Pharmaceutical Co., Ltd. Thiazole derivative and pharmaceutical use thereof
WO2016183173A1 (en) * 2015-05-12 2016-11-17 Avista Pharma Solutions Antiparasitic compounds
US10138227B2 (en) * 2016-06-03 2018-11-27 Abbvie S.Á.R.L. Heteroaryl substituted pyridines and methods of use
TW201811766A (zh) * 2016-08-29 2018-04-01 瑞士商諾華公司 N-(吡啶-2-基)吡啶-磺醯胺衍生物及其用於疾病治療之用途

Also Published As

Publication number Publication date
CO2022007953A2 (es) 2022-09-09
IL292966A (en) 2022-07-01
EP4058439A1 (en) 2022-09-21
CA3158057A1 (en) 2021-05-20
JOP20220105A1 (ar) 2023-01-30
MX2022005809A (es) 2022-06-08
CN115003659A (zh) 2022-09-02
CL2022001245A1 (es) 2023-03-10
KR20220115829A (ko) 2022-08-18
AU2020384279A1 (en) 2022-05-26
ECSP22046050A (es) 2022-08-31
BR112022009185A2 (pt) 2022-07-26
US20240002374A1 (en) 2024-01-04
WO2021097057A1 (en) 2021-05-20
JP2023500408A (ja) 2023-01-05

Similar Documents

Publication Publication Date Title
PE20221461A1 (es) Heteroarilaminosulfonamidas de 5 miembros para tratar afecciones mediadas por una actividad deficiente de cftr
PE20200668A1 (es) Oxadiazoles fungicidas
PE20221460A1 (es) Heteroarilaminosulfonamidas de 6 miembros para tratar enfermedades y afecciones mediadas por la actividad de cftr deficiente
PE20210397A1 (es) Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores hpki para tratar el cancer
JP2016528201A5 (es)
PE20230238A1 (es) Inhibidores de kras g12c
PE20191147A1 (es) Modulador de regulador de conductancia de transmembrana de fibrosis quistica, composiciones farmaceuticas, metodos de tratamiento y proceso para producir el modulador
ECSP077370A (es) Composiciones fungicidas
RU2010154400A (ru) Гетероциклическое соединение
HRP20151370T1 (hr) Derivati benzotiazola kao sredstva protiv raka
JP2016503009A5 (es)
PE20161225A1 (es) 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer
AR086828A1 (es) Compuestos heterociclicos fusionados como moduladores del canal ionico
NZ601408A (en) Novel 3-hydroxy-5-arylisothiazole derivative
JP2012501313A5 (es)
NO20076478L (no) Substituerte oksadiazolderivater som positive allosteriske modulatorer av metabotrope glutamatreseptorer
NO20076479L (no) Nye oksadiazolderivater og anvendelse derav som positive allosteriske metabotropiske modulatorer av glutamatreseptorer
RU2018103198A (ru) Новые соединения циклического n-карбоксамида, применяемые в качестве гербицидов
JP2018531236A5 (es)
NZ601526A (en) Inhibitors of diacylglycerol acyl transferase
RU2012116877A (ru) Соединения 2-пиридона, применяемые в качестве ингибиторов нейтрофильной эластазы
AR109437A1 (es) Derivados de n-(piridin-2-il)piridina-sulfonamida y su uso en el tratamiento de enfermedades
JP2017516796A5 (es)
PE20141943A1 (es) Antagonistas de trpv4
PE20131399A1 (es) Composicion fungicida que comprende un derivado de tetrazoliloxima y un derivado de tiazolilpiperidina